David Rosmarin, MD
Dermatology · Indianapolis, INNPI 1730353665
Payments from drug & device makers
Across 1,459 payments — averaging $3039.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.1M
- Pfizer$759K
- Incyte Corporation$641K
- Eli Lilly$471K
- AbbVie$448K
- Amgen$213K
- plus $830K from 23 others
Across 29 payments — averaging $816.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$14K
- Amgen$3K
- Regeneron$2K
- Eli Lilly$2K
- Novartis$2K
- AbbVie$1K
What the payments were for
- Consulting fees$420,37237%
- Speaking & faculty fees$608,29454%
- Travel & lodging$78,4577%
- Food & beverage$16,1731%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 92 | $1,073,793 |
| Pfizer | 141 | $758,697 |
| Incyte Corporation | 343 | $640,718 |
| Eli Lilly | 148 | $470,503 |
| AbbVie | 159 | $448,033 |
| Amgen | 61 | $212,953 |
| Sanofi | 73 | $120,347 |
| E.r. Squibb & Sons, L.L.C. | 19 | $118,679 |
| Lilly USA, LLC | 152 | $116,055 |
| Regeneron | 29 | $67,255 |
| Regeneron Healthcare Solutions, Inc. | 67 | $65,395 |
| Janssen Scientific Affairs, LLC | 36 | $48,668 |
| Janssen Research & Development, LLC | 14 | $46,025 |
| Bristol Myers Squibb | 25 | $36,550 |
| Astrazeneca UK Limited | 1 | $36,390 |
| Dermira, Inc. | 8 | $28,939 |
| Dermavant Sciences, Inc. | 21 | $27,535 |
| Boehringer Ingelheim | 4 | $23,850 |
| Merck | 21 | $19,787 |
| Johnson & Johnson | 19 | $18,644 |
| Taro Pharmaceuticals USA, Inc. | 6 | $16,639 |
| UCB, Inc. | 6 | $12,095 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $6,327 |
| CSL Behring | 4 | $6,310 |
| Sun Pharmaceutical Industries Inc. | 1 | $5,000 |
| UCB SA | 1 | $4,479 |
| Boehringer Ingelheim Espana S.A. | 3 | $3,944 |
| Almirall LLC | 1 | $800 |
| Kyowa Kirin Co., Ltd | 1 | $400 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,434,808 in reported general payments places this provider in the 95th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Indianapolis
- Scott FretzinIndianapolis$9.8M
- Kenneth DawesIndianapolis$2.2M
- Ginat MirowskiIndianapolis$1.8M
- Christopher ObeimeIndianapolis$907K
- Priya YoungIndianapolis$492K
- Nikolajs PerdueIndianapolis$302K
- Matthew TurnerIndianapolis$203K
- Stephen WolvertonIndianapolis$29K
- Annette DinneenIndianapolis$22K
- Michael IsaacsIndianapolis$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.